Stocks · News reference

Rein Therapeutics Announces Nature Communications Publication Of First-In-Human LTI-03 Data In 24 IPF Patients, Says Drug Reduced Multiple Fibrosis And Inflammation Markers

Aug 4, 2026, 12:05 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 20, 2026, 12:02 PMBenzinga Newsdesk
FDA Grants Rein Therapeutics Fast Track Designation For LTI-03
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03
Read original at benzinga
RNTX
BenzingaAug 18, 2026, 11:36 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.
Read original at benzinga
RNTX
BenzingaAug 14, 2026, 10:47 AMBenzinga Newsdesk
Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) Estimate
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 64.29 percent increase over losses of $(0.28) per share
Read original at benzinga
RNTX